Overview of Ziana

What is Ziana? Overview

Property	Description
Active Ingredients	Clindamycin Phosphate, Tretinoin
Form	Topical Gel
Pharmacological Class	Antibacterial Agent and Retinoid Combination
Administration	Topical (Applied to the skin)
Origin	Synthetic/Semi-Synthetic Combination

What Type of Medicine is Ziana?

Clindamycin Phosphate and Tretinoin Gel, known by the trade name Ziana, is defined as a Fixed-Dose Combination (FDC) topical dermatological agent that contains two distinct, synthetic active compounds. It is classified as an Antibacterial Agent combined with a Retinoid, and is intended solely for topical administration to the skin, primarily targeting adolescents and adults. The inclusion of two active components in a single preparation is a strategic design choice clinically recognized for providing a more comprehensive approach than treatments relying on a single active drug. This FDC product received approval for its specific formulation and components.

What is Ziana Composed Of?

This prescription medicine is made up of two active ingredients: Clindamycin Phosphate and Tretinoin, which are suspended within an Aqueous/Alcoholic Gel Base. Clindamycin Phosphate is a semi-synthetic derivative of lincomycin, belonging to the lincosamide class of antibiotics. Tretinoin, chemically known as all-trans-retinoic acid, is a synthetic compound belonging to the retinoid family, which are structural and functional analogs of Vitamin A. The formulation specifically utilizes a Gel Base, which is a non-greasy vehicle commonly preferred in topical preparations for its favorable cosmetic acceptance and localized delivery of the active substances.

What is the General Purpose of This Combination Gel?

The general purpose of this combination gel is to leverage the synergistic effect of its two components to target the bacterial and cellular processes underlying specific skin blemishes. The Clindamycin Phosphate provides antimicrobial action to control the population of bacteria associated with inflammation, while the Tretinoin component facilitates keratolytic effects to regulate skin cell turnover and prevent the formation of pore blockages. This dual approach is essential for achieving a thorough improvement in the appearance and condition of affected skin.

What side effects are possible with Ziana?

Possible Side Effects and Safety Information

The safety profile of Ziana Gel is defined by localized skin reactions and a critical systemic risk related to the clindamycin component, as documented in regulatory sources.

Adverse Reaction Scope

Category	Description
Key Adverse Reactions	Local cutaneous reactions (erythema, scaling, irritation); Gastrointestinal risks.
Frequency Classification	Most reactions are classified as Common (incidence ge 1%), with some local effects reported as Very Common in clinical studies.
System-Organ Classes	Skin and Subcutaneous Tissue Disorders (e.g., dryness, pruritus); Gastrointestinal Disorders (colitis, diarrhea); Infections and Infestations (e.g., nasopharyngitis).

Safety Constraints and Serious Risk

Serious adverse reactions include colitis, specifically pseudomembranous colitis, which has been reported with topical clindamycin and can be severe. This necessitates specific contraindications, including a patient history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Furthermore, the tretinoin component causes photosensitivity, requiring caution regarding exposure to sunlight and UV light.

Local skin reactions typically peak around two weeks of therapy and then gradually subside, though the onset of severe colitis may occur several weeks following cessation of therapy.

Safety is not established in children younger than 12 years of age, and use is not recommended during pregnancy due to the teratogenicity risks associated with oral retinoids.

Connection to the Overall Safety Profile

Regulatory information establishes that the medicine’s risk is predominantly structured by expected, transient local irritation combined with a low-frequency but high-severity systemic gastrointestinal risk. This is further limited by population-specific restrictions and absolute contraindications based on pre-existing medical conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Clindamycin Phosphate and Tretinoin Gel describes overdose risks primarily in two categories: local effects from excessive application and serious systemic effects from the absorbed antibiotic component.

Overusing the topical gel may result in severe local irritation, including marked redness (erythema), scaling, and increased discomfort at the application site. These manifestations are generally attributed to the Tretinoin component.

Regulatory documentation emphasizes that systemic absorption of clindamycin is demonstrated following topical application, carrying the risk of serious complications. The most severe documented manifestation of systemic exposure is colitis, including Pseudomembranous Colitis, which is explicitly noted as a life-threatening outcome that may result in death.

Immediate medical attention is required for any signs of this systemic risk, particularly severe persistent diarrhea, bloody diarrhea, or severe abdominal cramps. The product must be discontinued if significant diarrhea occurs. Management is described as symptomatic and supportive treatment, as no specific antidote is known for this combination gel. Regulatory labeling notes that due to minimal systemic absorption, moderate renal or hepatic impairment is not expected to result in systemic exposure of clinical concern.

Therapeutic Uses of Ziana

What Ziana Treats: Main Uses and Benefits

The primary therapeutic utility of Ziana Gel is used for managing Acne Vulgaris in adolescents and adults; it is an antibiotic and retinoid combination product that is commonly used in this therapeutic domain.

This topical gel is generally applied in conditions presenting with systemic or localized discomfort, including symptoms such as papules, pustules, blackheads, and whiteheads (comedones). It is relevant when groups of symptoms appear suddenly or fluctuate, and the treatment helps address symptom clusters that may become intense or disruptive. The medication is commonly applied in scenarios relevant when supportive symptom management is appropriate for symptoms of mild to moderate severity.

“This application supports the patient during difficult episodes by easing distress associated with active blemishes and assists with maintaining functional stability.”

The usage provides support that helps ease the overall symptom burden, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptom Clusters
This combination therapy is relevant for managing symptoms related to red, raised blemishes and blocked pores that often occur together in acne vulgaris.

Regulatory References

NIH DailyMed Drug Label for Clindamycin Phosphate and Tretinoin Gel

Eligibility and Restrictions for Use

Who Can and Cannot Use Ziana? (Clindamycin Phosphate and Tretinoin Gel)

Official regulatory documents define specific populations permitted to use Ziana and groups for whom use is prohibited or restricted.

Eligibility and Approved Age Groups

Ziana is approved for the topical treatment of Acne Vulgaris in patients 12 years of age and older. Safety and effectiveness have not been established for children under 12 years of age or adults over 65 years of age.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. It is also contraindicated for patients with known hypersensitivity to clindamycin, tretinoin, lincomycin, or any component of the formulation.

Contraindicated Populations (Mandatory Exclusions)
Women who are pregnant or planning a pregnancy
Patients with a history of skin cancer, rosacea, or acute eczemas (based on European labeling)

Restricted and Conditional Use

Use is not recommended while breastfeeding. The gel must not be used on areas of the skin with sunburn or open wounds until fully healed. The product is not indicated for treating severe acne types, such as deep cystic nodular acne.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Ziana Gel (Clindamycin Phosphate and Tretinoin) through specific constraints related to antimicrobial, pharmacodynamic, and environmental co-exposures.

The combination is prohibited with erythromycin-containing products because of documented antagonism against the clindamycin component. This constitutes a formal contraindicated combination.

The clindamycin component introduces a risk of Pharmacodynamic (PD) enhancement with systemically administered agents. Specifically, the regulatory profile states that clindamycin has neuromuscular blocking properties that may enhance the action of other Neuromuscular Blocking Agents. Furthermore, co-administration with Vitamin K Antagonists (like warfarin) has been associated with reports of increased coagulation tests (PT/INR) and bleeding.

Interactions related to the tretinoin component are centered on additive toxicity and local effects. Co-administration with oral retinoids or therapeutic Vitamin A supplements exceeding 10,000 units per day may result in additive adverse effects. Local constraints advise against the use of other topical medications with a strong drying effect or products containing high concentrations of alcohol, astringents, spices, or lime, as these may cause increased skin irritation.

Finally, mandatory environmental restrictions apply: Ultraviolet (UV) light exposure, including sunlight and sunlamps, must be avoided. Use is restricted until recovery from sunburn, and exposure to very windy or cold weather should also be avoided. Regulatory documents note that due to low systemic absorption, moderate renal or hepatic impairment is not expected to result in systemic exposure of clinical concern.

Mechanism of Action

Normalizing Skin Cell Turnover (Follicular Homeostasis)

The tretinoin component acts as an agonist for nuclear Retinoic Acid Receptors ( RARs), primarily RARgamma, within follicular keratinocytes. This binding modulates gene transcription to normalize the differentiation and subsequent shedding (keratinization) of epithelial cells lining the hair follicle. This action results in a decreased tendency for the formation of follicular obstructions (microcomedones), influencing the structural pathway of the pilosebaceous unit.

Interfering with Microbial Factor Synthesis

The clindamycin component acts as an inhibitor by binding to the bacterial 50S ribosomal subunit of Cutibacterium acnes, thereby interfering with protein synthesis. This modulates the local population of C. acnes and decreases the release of bacterial metabolic factors. The resulting effect is the modulation of localized immune cell activity and the associated inflammatory cascade.

Synergistic Pathway Co-Modulation

The mechanism involves the simultaneous co-modulation of two distinct biological processes: follicular epithelial homeostasis (via RAR agonism) and microbial factor synthesis (via 50S ribosomal inhibition). This multi-modal action influences both the cellular process of obstruction and the microbial-driven inflammatory cascade, supporting a comprehensive pathway adjustment within the skin.

Dosage and Administration Information

How to Use Ziana: Official Administration Guidelines

Clindamycin Phosphate and Tretinoin Gel is a fixed-dose combination product intended solely for topical administration to the skin. The gel is not indicated for oral, ophthalmic (eye), or intravaginal use. The product is officially designated for use in patients 12 years of age or older.

Standard Labeled Usage Protocol

Feature	Official Administration Guideline
Route & Form	Topical Gel (1.2% Clindamycin Phosphate, 0.025% Tretinoin)
Dosing Schedule	Once daily
Timing	Applied in the evening, typically at bedtime
Dose Amount	Approximately a pea-sized amount
Application Area	The entire affected face

The official administration protocol requires that the dose—a pea-sized amount—be applied in a thin layer to the entire affected facial area once daily. The medication is to be applied only after the face has been gently washed with a mild soap and warm water, then patted dry. Application must avoid contact with the eyes, mouth, angles of the nose, and mucous membranes. Increasing the application frequency or amount beyond the recommended single daily pea-sized dose is explicitly stated not to provide faster results.

Due to the nature of one of the active components, the use protocol includes a mandatory environmental constraint: individuals using this product are required to use a broad-spectrum sunscreen and wear protective apparel on treated areas when exposed to sunlight. The typical treatment course utilized in efficacy studies spans 12 weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ziana

Evidence for Use in Mild to Moderate Acne Vulgaris

The research base for the Clindamycin Phosphate and Tretinoin combination gel involves controlled studies where research was conducted for conditions characterized by fluctuating or episodic manifestations like papules, pustules, and blocked pores. Most of the foundational evidence was derived from multiple Randomized Controlled Trials (RCTs), where researchers observed outcomes over defined time intervals. These studies were conducted in research scenarios exploring how symptoms change over time and to collect outcomes linked to inflammatory or irritative states.

In these trials, the combination gel was studied for comparison against three main groups: the antibiotic component (Clindamycin) alone, the retinoid component (Tretinoin) alone (monotherapy arms), and a non-medicated gel base (vehicle control). The main measurements taken in these trials included lesion counts, where researchers examined the absolute and percentage change from baseline in both red, raised blemishes (inflammatory lesions) and clogged pores (non-inflammatory lesions).

Comparing the Combination to Single Ingredients

Studies explored how the measured patterns in the combination group compared to those observed in the single-ingredient groups or the non-medicated base group. Researchers also monitored overall skin appearance using an Investigator's Global Assessment (IGA), where clinicians tracked the proportion of individuals who achieved pre-defined categories of change. Findings describe group patterns observed in these studies, where researchers monitored and compared the outcomes related to symptom axes across the different treatment groups during the short-term study period.

Long-Term Research and Follow-up Durations

The clinical trials used to establish the initial evidence for the gel typically had follow-up durations that were limited to 12 weeks for the primary assessment of changes. This short-term research explores episodic symptom changes and provides insight into short-term changes. While the primary outcomes related to symptom axes were assessed during this short period, some subsequent open-label studies have observed participants for up to 52 weeks. However, there is limited information for long-term outcomes that are sustained beyond the initial three-month period, meaning data on sustained patterns over time is not fully established under the controlled conditions of the pivotal trials.

Research in Specific Study Populations

The core evidence supporting the combination gel was evaluated in a defined group: adolescents and adults aged 12 years and older with acne severity classified as mild to moderate. This means that the research highlights what is known for these specific groups. Data for certain groups remain insufficient. For instance, limited data are available exploring evidence derived from studies focused on individuals with severe or nodulocystic acne. Additionally, children under 12 years of age and other special populations were generally excluded from the main regulatory trials. Consequently, the results apply only to the populations studied. Research does not determine whether an individual in a non-studied group will exhibit similar patterns.

Key Areas of Research Uncertainty

One primary limitation is that long-term effects are not fully established, as the main follow-up durations were limited to 12 weeks. This means that continuous evidence over many months or years is less robustly characterized. Furthermore, because the research examined specific acne severity levels (mild to moderate), data for certain groups remain insufficient for those with very severe acne. While studies monitored short-term changes, the research does not provide context or individual predictions about how the combination gel studies monitored the combination gel in scenarios related to long-term usage patterns.

Key Studies & References

DailyMed Drug Label for Clindamycin Phosphate and Tretinoin Gel

Frequently Asked Questions (FAQ)

Common questions about Ziana (FAQ)

Q: Is a generic version of Ziana gel available to patients?

The drug is available under its established generic name, Clindamycin Phosphate and Tretinoin Gel, in the same strength and form as the brand name product. This formulation is listed in official sources under both its brand name and its established generic name.

Q: How is Ziana different from topical retinoids that do not contain clindamycin?

Ziana is defined in official documents as a Fixed-Dose Combination product. This means it contains two distinct active ingredients: a retinoid (tretinoin) and an antibacterial agent (clindamycin). This combination is designed to target two separate processes in acne formation: cellular obstruction and microbial factors.

Q: Is Ziana gel generally safe to use on parts of the body other than the face?

The product information states that the gel is indicated for the topical treatment of acne on the entire affected facial area. It is not officially indicated for use on other parts of the body, nor is it intended for oral, eye, or internal use.

Q: What is the typical timeframe before noticing an initial improvement with Ziana?

Official prescribing information describes the observation periods used in clinical trials. The clinical efficacy trials used for regulatory approval typically utilized a treatment course that spanned 12 weeks for the primary assessment of changes in acne symptoms.

Q: What does it mean if Ziana is not showing any improvement after 12 weeks of consistent use?

Clinical efficacy trials used for regulatory review were conducted over a period of 12 weeks. Data regarding sustained patterns and long-term changes beyond that period are not fully established under the controlled conditions of the pivotal trials.

Q: Is it common to experience a burning or stinging sensation immediately after applying Ziana?

Local skin sensations are a commonly reported reaction to the gel. According to official adverse reaction data, reactions including burning or stinging are listed among the reported effects.

Q: What are the signs of a potential severe or serious side effect that would require immediate medical attention?

Serious warnings for the product address the potential for rare but severe gastrointestinal issues, such as colitis. These warnings include descriptions of signs such as severe diarrhea, bloody diarrhea, or severe abdominal cramps, which warrant immediate medical review.

Q: Can Ziana be used at the same time as other topical acne medications?

Regulatory documents state that concomitant use with erythromycin-containing products is contraindicated (prohibited). Other topical acne therapy should be used with caution due to the risk of cumulative irritancy (combined irritation).

Q: Does using Ziana at the same time as benzoyl peroxide cause any issues?

The official label advises caution with the use of other topical treatments due to a possible cumulative irritancy effect. This caution specifically applies to agents that cause peeling or have a strong drying effect.

Q: Are there any specific cleansers or face washes that should be avoided while using Ziana?

Official guidance advises against using other topical products that may increase skin irritation. This includes products with a strong drying effect or those containing high concentrations of alcohol, astringents, spices, or lime.

Q: Does Ziana interact with common oral antibiotics or medicines taken by mouth?

According to the official label, Ziana may interact with certain medicines taken by mouth. Specifically, the clindamycin component may enhance the action of certain Neuromuscular Blocking Agents. There is also a risk of affecting blood coagulation when used with Vitamin K Antagonists (e.g., warfarin).

Q: Is Ziana intended for short-term use only, or can it be used for long-term maintenance?

Clinical trials used to establish the initial evidence for the gel had follow-up durations limited to 12 weeks for primary assessment. Data on sustained patterns and continuous long-term effects beyond the 12-week study duration are not fully established.

Q: Does Ziana require a medical professional's prescription to obtain it?

The product is listed in official regulatory databases as a prescription medicine. This means Ziana requires authorization from a licensed healthcare professional to be obtained.

Q: Can patients with a history of eczema safely use Ziana gel?

Official regulatory labeling, such as the European SmPC, states that the medicine is contraindicated for patients with acute eczemas (a type of severe skin inflammation). Official warnings note that due to the documented skin irritation risks, caution is appropriate in the presence of eczema.

Q: Is Ziana a suitable option for adult-onset acne, or is it only for teenage acne?

Official documents state that Ziana is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. This approved population includes both adolescents and adults.

How should Ziana be stored and disposed of?

ZIANA Gel must be stored and handled according to specific conditions detailed in the official regulatory labeling to ensure its stability.

Storage Requirements

Item	Required Official Condition
Temperature Range	Store at 25 C (77 F); excursions permitted from 15 C to 30 C (59 F to 86 F).
Environmental Protection	Protect from heat, protect from light, and protect from freezing.
Container Rule	Keep the tube tightly closed when not in use.
Child Safety	Keep out of the reach of children.

Disposal Instructions

Official disposal guidance states that the medicine no longer needed should be disposed of in a safe manner. Patients are instructed to consult a healthcare professional for the proper procedures to discard any unused or expired product according to local regulations. The product is flammable.

Ziana